New drug cocktail aims to stop advanced nasopharyngeal cancer in its tracks
NCT ID NCT07385079
First seen Feb 03, 2026 · Last updated Jun 16, 2026 · Updated 19 times
Summary
This phase 3 trial tests whether adding the drug anlotinib to standard chemoradiotherapy and immunotherapy can improve outcomes for people with high-risk nasopharyngeal cancer. About 412 adults aged 18-65 with advanced-stage disease will be randomly assigned to receive either the standard treatment or the standard treatment plus anlotinib. The main goal is to see if the combination delays cancer recurrence or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.